— BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period.
— Net loss per share was cents per share, narrower than a loss of 6 cents per share last year, due to higher share count.
— R&D expenses rose 11% to $5.6 million, primarily due to costs associated with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results expected by the end of the year.
— BLRX shares are down 75% so far this year.
McDonald’s Corporation (NYSE: MCD) Wednesday reported stronger-than-expected earnings and revenues for the second quarter of 2021. The fast-food chain reported revenues of $5.89 billion for the June quarter, up 57%
Shopify (NYSE: SHOP) reported second-quarter 2021 financial results before the regular market hours on Wednesday. The ecommerce giant reported Q2 revenue of $1.12 billion, up 57% year-over-year and higher than
Pfizer Inc. (NYSE: PFE) reported second quarter 2021 earnings results today. Total revenue increased 92% year-over-year to $19 billion. GAAP net income increased 59% YoY to $5.5 billion, or $0.98